OncoVee™-mini-patient-derived xenograft guided adjuvant chemotherapy treatment for resectable gastric cancer

Table 4 Univariate and multivariate Cox proportional hazards regression analysis of overall survival

Characteristics	Mean recurrence-free survival months	P value	Multivariate adjusted hazard ratio (95% confidence interval)1	P value
Treatment		0.036	0.283 (0.081-0.997)	0.050
MiniPDX group, n = 16	54.5 (46.9-62.1)
Experimental treatment group, n = 20	43.5 (36.2-50.7)
Age group		0.312	NA	NA
≤ 60, n = 24	50.6 (43.6-57.5)
> 60, n = 12	42.8 (33.6-52.1)
Sex		0.078	NA	NA
Male, n = 22	52.1 (45.2-59.0)
Female, n = 14	39.1 (31.9-46.3)
T-stage of primary tumor1		0.208	NA	NA
pT1, n = 10	50.3 (41.7-58.9)
pT2, n = 8	52.6 (42.0-63.2)
pT3, n = 15	45.1 (36.0-54.2)
pT4, n = 3	26.3 (18.0-34.6)
N-stage of primary tumor1		0.465	NA	NA
N0, n = 19	48.3 (40.5-56.1)
N1, n = 6	55.7 (44.3-67.0)
N2, n = 2	45.5 (24.0-67.0)
N3, n = 9	40.0 (30.8-49.2)
Stage of AJCC1		0.554	NA	NA
Stage 1, n = 16	51.3 (44.0-58.6)
Stage 2, n = 9	47.7 (34.5-60.8)
Stage 3, n = 11	42.4 (32.9-52.0)

¹Tumor stage was defined according to the American Joint Committee on Cancer tumor-node-metastasis staging system (8^th edition).

MiniPDX: Mini patient-derived xenograft; AJCC: American Joint Committee on Cancer; NA: Not available.